A Phase 3 interventional study of Paracetamol and Caffeine and Ibuprofen in Pain, sponsored by GlaxoSmithKline. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-01.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.
Among the 137 studies testing acetaminophen in Pain, this one is the 13th largest by enrollment, is one of 11 that started in 2013, is one of 22 in phase 3, and was the 58th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Horizon Health Network · Sites in Canada
Ages 19+
University of Gaziantep · Sites in Turkey
Ages 18–75
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–45 · Women only · Healthy volunteers
Baskent University · Sites in Turkey
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 25 · Phase 4 67
First in 2003; this study’s year is marked. 11 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 365 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 95 across the 137 interventional studies. Of the 115 that completed or were terminated, 53 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 137 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
30 studies in Pain by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 30 finished, 15 (50%) have results posted.
Among the 30 studies in Pain by GlaxoSmithKline, this one is the 3rd largest by enrollment, is one of 2 that started in 2013, is one of 4 in phase 3, and was the 14th registered.
GlaxoSmithKline’s Pain studies by the year they started, since 2003.
4 of the studies testing acetaminophen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07368738Horizon Health NetworkIntravenous Acetaminophen and Ketorolac for Pain Management During Extracorporeal Shockwave Lithotripsy | 2027-04 |
| NCT06613178McGill University Health Centre/Research Institute of the McGill University Health CentreIntravenous Acetaminophen After Cardiac Surgery - Definitive Study | 2027-07-01 |
| NCT07536425Western Galilee Hospital-NahariyaPreoperative Indomethacin and Paracetamol for Pain Management During Oocyte Retrieval in IVF Patients | 2027-10-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 137 studies testing acetaminophen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 30 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this multi-center study is to assess the efficacy of headache relief of new paracetamol/caffeine formulation compared to placebo and ibuprofen in episodic tension-type headache (ETTH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants in good general health, and with diagnosis of ETTH with following conditions:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two caplets of paracetamol/caffeine combination plus 2 placebo caplets to be administered
Drug: Paracetamol and Caffeine
Two ibuprofen caplets plus two placebo caplets to be administered
Drug: Ibuprofen
Four placebo caplets to be administered
Other: Placebo
Drug pages: Acetaminophen · Caffeine
Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine
Caplets containing 200 mg of ibuprofen
Matching placebo caplets
Sum of Pain Intensity Difference (SPID) of Treatment and Placebo at 4 Hours
SPID was calculated as the weighted sum of Pain (Headache) intensity differences at 4 hours post dose. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120, 120-180, 180-240 minutes. The range of SPID at 4 hours post dose was from -12 to 4". PID was calculated as difference of pain intensity (PI) at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).
Time frame: Up to 4 hours post dose
Sum of Pain Intensity Difference (SPID) at 1, 2 and 3 Hours
SPID was calculated as the weighted sum of Pain (Headache) intensity differences at 1, 2 and 3 hours post dose. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60 minutes for SPID at 1 hour post dose. The range of SPID at 1 hour post dose was from -3 to 1. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120 minutes for SPID at 2 hours post dose . The range of SPID at 2 hours post dose was from -6 to 2. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120, 120-180 minutes for SPID at 3 hours post dose. The range of SPID at 3 hours post dose was from -9 to 3. PID was calculated as difference of pain intensity (PI) at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).
Time frame: From (Baseline) 0 to 1 hour, 0 to 2 hours, and 0 to 3 hours post dose
Number of Participants With Perceptible Pain Relief
Time frame: Baseline up to 4 hours
Time to Perceptible Headache Relief
Time to perceptible headache relief was assessed as the time when participants achieve pain relief scores (PRS) more than or equal to 1.
Time frame: Baseline up to 4 hours
Number of Participants With Meaningful Pain Relief
Time frame: Baseline up to 4 hours
Time to Meaningful Headache Relief
Time to meaningful headache relief was assessed as time when participants reported a PRS ≥ 2.
Time frame: Baseline up to 4 hours
Total Pain Relief (TOTPAR)
TOTPAR was calculated as the weighted sum of pain relief scores (PRS) at each time point. PRS was assessed on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). The range for TOTPAR for different time points were as follows: from 0 to 4 for TOTPAR at 1 hour post dose, from 0 to 8 for TOTPAR at 2 hours post dose, from 0 to 12 for TOTPAR at 3 hours post dose, and from 0 to 16 for TOTPAR at 4 hours post dose.
Time frame: From (Baseline) 0 to 1, from 0 to 2, from 0 to 3 and from 0 to 4 hour post dose
Area Under the Time-Response Curve for Change in Headache Intensity and Headache Relief (SPRID)
SPRID was measured as sum of TOTPAR and SPID. SPID and TOTPAR were calculated as weighted sums of PID and PRS at each measurement time point, respectively. PID at each time point was calculated as difference of PI at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache). PRS was assessed on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). The range of SPRID for different time points were as follow: from-3 to 5 for SPRID at 1 hour post dose, from -6 to 10 for SPRID at 2 hours post dose, from -9 to 15 for SPRID at 3 hours post dose, and from -12 to 20 for SPRID at 4 hours post dose.
Time frame: From (Baseline) 0 to 1 hour, 0 to 2 hours, 0 to 3 hours and 0 to 4 hours post dose
Global Evaluation of Response to Treatment
Global evaluation of treatment response was measured by a score in a scale from: 0-very poor, 1-poor, 2-neutral \[neither poor nor good\], 3-good, or 4-very good).
Time frame: 4 hours
Rate of Rescue Medication
Number of participants that took rescue medication over the total number of participants for a given treatment group
Time frame: 4 hours
Change From Baseline in Headache Pain Intensity
Change from baseline in headache pain intensity was calculated as the change (difference) from baseline PI with PI at each time-point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).
Time frame: At 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, and 240 min.
Headache Relief
The participant assessed headache relief of each treated qualifying headache at 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, and 240 minutes post treatment on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). higher headache relief score indicates better outcome.
Time frame: At 10 min. 15 min., 20 min., 25 min., 30 min., 40 min., 50 min., 60 min., 90 min., 120 min., 180 min., 240 min.,
Number of Pain Free Participants
Number of participants with complete relief was calculated as the number of participants who reported PRS = 4-complete relief at 1 hour and 2 hours post dose.
Time frame: 1 hour and 2 hour post dose
Time to the Use of Rescue Medication.
Time taken by the participants to use the rescue medication
Time frame: Up to 4 hours
Participants were recruited at clinical sites in the United States.
| Milestone | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| Started | 65 | 66 | 34 |
| Completed | 62 | 64 | 34 |
| Not completed | 3 | 2 | 0 |
| Withdrew: Screen failure | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Withdrew: Technical issues | 1 | 0 | 0 |
SPID was calculated as the weighted sum of Pain (Headache) intensity differences at 4 hours post dose. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120, 120-180, 180-240 minutes. The range of SPID at 4 hours post dose was from -12 to 4". PID was calculated as difference of pain intensity (PI) at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).
| score on a scale | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| Sum of Pain Intensity Difference (SPID) of Treatment and Placebo at 4 Hours | -6.13 ± 2.164 | -5.78 ± 2.098 | -5.86 ± 2.339 |
SPID was calculated as the weighted sum of Pain (Headache) intensity differences at 1, 2 and 3 hours post dose. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60 minutes for SPID at 1 hour post dose. The range of SPID at 1 hour post dose was from -3 to 1. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120 minutes for SPID at 2 hours post dose . The range of SPID at 2 hours post dose was from -6 to 2. The time-intervals used were 0-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-50, 50-60, 60-90, 90-120, 120-180 minutes for SPID at 3 hours post dose. The range of SPID at 3 hours post dose was from -9 to 3. PID was calculated as difference of pain intensity (PI) at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).
| score on a scale | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| At 1 hour (n=62, 61, 33) | -0.64 ± 0.488 | -0.56 ± 0.418 | -0.57 ± 0.505 |
| At 2 hour (n=62, 61, 33) | -2.21 ± 1.106 | -2.02 ± 1.002 | -2.04 ± 1.088 |
| At 3 hour (n=61, 62, 32) | -4.09 ± 1.524 | -3.86 ± 1.342 | -3.97 ± 1.528 |
| number of participants | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| number of participants | 62 | 61 | 33 |
| number of censored participants | 0 | 1 | 0 |
Time to perceptible headache relief was assessed as the time when participants achieve pain relief scores (PRS) more than or equal to 1.
| minutes (min.) | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| Time to Perceptible Headache Relief | 27.00 ± 31.274 | 29.67 ± 41.173 | 27.00 ± 38.042 |
| number of participants | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| number of participants | 61 | 60 | 32 |
| number of censored participants | 1 | 2 | 1 |
Time to meaningful headache relief was assessed as time when participants reported a PRS ≥ 2.
| min. | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| Time to Meaningful Headache Relief | 43.33 ± 49.342 | 54.17 ± 49.095 | 46.67 ± 61.477 |
TOTPAR was calculated as the weighted sum of pain relief scores (PRS) at each time point. PRS was assessed on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). The range for TOTPAR for different time points were as follows: from 0 to 4 for TOTPAR at 1 hour post dose, from 0 to 8 for TOTPAR at 2 hours post dose, from 0 to 12 for TOTPAR at 3 hours post dose, and from 0 to 16 for TOTPAR at 4 hours post dose.
| score on a scale | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| Baseline-1 hour (62, 61, 33) | 1.31 ± 0.922 | 1.17 ± 0.801 | 1.14 ± 0.864 |
| Baseline-2 hour (62, 61, 33) | 4.28 ± 1.818 | 4.05 ± 1.740 | 3.82 ± 1.886 |
| Baseline-3 hour (61, 62, 33) | 7.84 ± 2.337 | 7.51 ± 2.250 | 7.35 ± 2.463 |
| Baseline-4 hour (59, 59, 33) | 11.57 ± 3.373 | 11.05 ± 3.774 | 10.47 ± 4.053 |
SPRID was measured as sum of TOTPAR and SPID. SPID and TOTPAR were calculated as weighted sums of PID and PRS at each measurement time point, respectively. PID at each time point was calculated as difference of PI at baseline (prior to the first dose) with PI at a given time point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache). PRS was assessed on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). The range of SPRID for different time points were as follow: from-3 to 5 for SPRID at 1 hour post dose, from -6 to 10 for SPRID at 2 hours post dose, from -9 to 15 for SPRID at 3 hours post dose, and from -12 to 20 for SPRID at 4 hours post dose.
| score on a scale | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| At 1 hour (n=62, 61, 33) | 0.67 ± 0.505 | 0.61 ± 0.424 | 0.57 ± 0.473 |
| At 2 hour (n=62, 61, 33) | 2.07 ± 0.957 | 2.03 ± 0.933 | 1.78 ± 1.116 |
| At 3 hour (n=61, 62, 32) | 3.75 ± 1.250 | 3.64 ± 1.285 | 3.38 ± 1.581 |
| At 4 hour (n=59, 59, 33) | 5.44 ± 1.890 | 5.28 ± 2.126 | 4.61 ± 2.613 |
Global evaluation of treatment response was measured by a score in a scale from: 0-very poor, 1-poor, 2-neutral \[neither poor nor good\], 3-good, or 4-very good).
| score on a scale | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| Global Evaluation of Response to Treatment | 2.88 ± 0.740 | 2.81 ± 0.834 | 2.66 ± 0.946 |
Number of participants that took rescue medication over the total number of participants for a given treatment group
| number of participants | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| Rate of Rescue Medication | 2 | 4 | 4 |
Change from baseline in headache pain intensity was calculated as the change (difference) from baseline PI with PI at each time-point. PI was assessed on a 4-point scale (0-no headache, 1-mild headache, 2-moderate headache, 3-severe headache).
| score on a scale | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| At 10 min. | -0.03 ± 0.166 | -0.01 ± 0.064 | -0.04 ± 0.211 |
| At 15 min. | -0.10 ± 0.322 | -0.06 ± 0.208 | -0.10 ± 0.366 |
| At 20 min. | -0.27 ± 0.439 | -0.21 ± 0.359 | -0.21 ± 0.464 |
| At 25 min. | -0.45 ± 0.501 | -0.34 ± 0.438 | -0.36 ± 0.582 |
| At 30 min. | -0.66 ± 0.625 | -0.51 ± 0.531 | -0.55 ± 0.697 |
| At 40 min. | -0.92 ± 0.727 | -0.75 ± 0.618 | -0.75 ± 0.729 |
| At 50 min. | -1.07 ± 0.769 | -0.93 ± 0.736 | -0.96 ± 0.725 |
| At 60 min. | -1.26 ± 0.831 | -1.17 ± 0.751 | -1.14 ± 0.706 |
| At 90 min. | -1.51 ± 0.748 | -1.48 ± 0.708 | -1.39 ± 0.733 |
| At 120 min. | -1.76 ± 0.704 | -1.73 ± 0.727 | -1.69 ± 0.725 |
| At 180 min. | -1.95 ± 0.529 | -1.90 ± 0.530 | -1.93 ± 0.561 |
| At 240 min. | -2.01 ± 0.575 | -1.91 ± 0.609 | -1.95 ± 0.591 |
The participant assessed headache relief of each treated qualifying headache at 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, and 240 minutes post treatment on a 5-point scale (0-no relief, 1-a little relief, 2-some relief, 3-a lot of relief, and 4-complete relief). higher headache relief score indicates better outcome.
| score on a scale | Paracetamol/ Caffiene Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| 10 min. | 0.07 ± 0.301 | 0.03 ± 0.140 | 0.11 ± 0.379 |
| 15 min. | 0.33 ± 0.660 | 0.16 ± 0.374 | 0.27 ± 0.635 |
| 20 min. | 0.68 ± 0.870 | 0.49 ± 0.670 | 0.60 ± 0.876 |
| 25 min. | 1.06 ± 1.059 | 0.77 ± 0.870 | 0.88 ± 0.986 |
| 30 min. | 1.37 ± 1.158 | 1.17 ± 1.072 | 1.22 ± 1.107 |
| 40 min. | 1.86 ± 1.341 | 1.62 ± 1.195 | 1.49 ± 1.182 |
| 50 min. | 2.15 ± 1.404 | 1.91 ± 1.356 | 1.82 ± 1.218 |
| 60 min. | 2.42 ± 1.380 | 2.34 ± 1.255 | 2.14 ± 1.213 |
| 90 min. | 2.85 ± 1.249 | 2.91 ± 1.162 | 2.68 ± 1.196 |
| 120 min. | 3.35 ± 0.962 | 3.37 ± 1.113 | 3.03 ± 1.206 |
| 180 min. | 3.69 ± 0.749 | 3.59 ± 0.907 | 3.44 ± 0.978 |
| 240 min. | 3.72 ± 0.795 | 3.55 ± 1.138 | 3.32 ± 1.155 |
Number of participants with complete relief was calculated as the number of participants who reported PRS = 4-complete relief at 1 hour and 2 hours post dose.
| number of participants | Paracetamol/Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| At 1 hour | 18 | 17 | 6 |
| At 2 hour | 38 | 41 | 20 |
Time taken by the participants to use the rescue medication
| Minutes | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| Time to the Use of Rescue Medication. | 239.00 ± 6.86 | 235.14 ± 24.06 | 235.55 ± 12.8 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paracetamol/ Caffeine Caplets | — | 0/62 (0%) | 4/62 (6.5%) |
| Ibuprofen Caplets | — | 0/62 (0%) | 3/62 (4.8%) |
| Placebo Caplets | — | 0/33 (0%) | 1/33 (3%) |
| Event | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets |
|---|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/62 | 0/62 | 1/33 |
| DyspepsiaGastrointestinal disorders | 1/62 | 0/62 | 0/33 |
| NasopharyngitisInfections and infestations | 1/62 | 0/62 | 0/33 |
| VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/62 | 0/62 | 0/33 |
| HYPOTHYROIDISMEndocrine disorders | 1/62 | 0/62 | 0/33 |
| FEELING JITTERYGeneral disorders | 1/62 | 0/62 | 0/33 |
| DEPRESSIONPsychiatric disorders | 0/62 | 1/62 | 0/33 |
| INSOMNIAPsychiatric disorders | 0/62 | 1/62 | 0/33 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 0/62 | 1/62 | 0/33 |
| PARANASAL SINUS DISCOMFORTRespiratory, thoracic and mediastinal disorders | 0/62 | 1/62 | 0/33 |
Demography data is available for 157 Participants only (safety Population).
| Age, Continuous(Years) | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets | Total |
|---|---|---|---|---|
| Mean | 39.9 ± 11.39 | 38.1 ± 13.13 | 38.5 ± 12.65 | 38.9 ± 12.32 |
| Sex: Female, Male(Participants) | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets | Total |
|---|---|---|---|---|
| Female | 46 | 44 | 23 | 113 |
| Male | 16 | 18 | 10 | 44 |
| Race (NIH/OMB)(Participants) | Paracetamol/ Caffeine Caplets | Ibuprofen Caplets | Placebo Caplets | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 6 | 4 | 14 |
| White | 56 | 55 | 28 | 139 |
| More than one race | 1 | 1 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Ran from Apr 2013 to primary completion in Mar 2015, 23 months.
Results were first posted in Jul 2017, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acetaminophen · Caffeine